New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
07:55 EDTEXAS, EXAS, EXASExact Sciences management to meet with Lazard Capital
Meetings to be held in the Mid-Atlantic area November 20-21 hosted by Lazard Capital.
News For EXAS From The Last 14 Days
Check below for free stories on EXAS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
11:47 EDTEXASOptions with increasing implied volatilit
Subscribe for More Information
August 18, 2014
08:05 EDTEXASExact Sciences risk/reward positive, says Canaccord
Canaccord said the scenario analysis of upcoming catalysts suggests positive risk/reward for the shares of Exact Sciences. The firm cited its potential for reimbursement approvals form both the CMS and commercial payers. Shares of Exact Sciences remain Buy rated with a $21 price target.
August 13, 2014
08:50 EDTEXASExact Sciences CMS approval expected by early September, says Canaccord
Canaccord met with Exact Sciences management and came away confident in the CMS' preliminary reimbursement amount, which the firm expects by early September. Canaccord also noted checks into the company's call center indicated strong interest in Cologuard and it expects targeted digital advertising to raise awareness of its product. The firm raised its price target on the stock to $21 from $20 and keeps its Buy rating on the shares.
August 12, 2014
09:35 EDTEXASActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOG C TSL EXAS BAC DNDN JNJ TSLA
09:21 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
07:24 EDTEXASExact Sciences FDA approval priced into shares, says Maxim
Subscribe for More Information
07:14 EDTEXASExact Sciences announces FDA approved Cologuard
Subscribe for More Information
August 11, 2014
16:24 EDTEXASFDA announces approval of Exact Sciences colorectal screening test
The FDA said it approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer. The FDA added that the Centers for Medicare & Medicaid Services proposes to cover the Cologuard test once every three years for Medicare beneficiaries who meet certain criteria. Cologuard is manufactured by Exact Sciences. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use